SAGA Diagnostics US, Inc.

Based in Scania, Sweden, and founded in 2016 by COO Lao Saal, and CTO Anthony George, SAGA Diagnostics AB, a. k. a. SAGA Diagnostics operates as a personalized cancer medicine and disease monitoring company that commercializes proprietary technologies to quantify cancer-associated genetic aberrations in tissue and liquid biopsy samples.

The company’s technology is also capable of achieving limits of detection down to 0. 001% mutant allele fraction. In April 2026, Foundation Medicine, Inc. , a portfolio company of Roche, Roche Venture Fund, Casdin Capital, Deerfield Management, Redmile Group, Kleiner Perkins, GV, and Third Rock Ventures acquired SAGA Diagnostics AB from Sciety, Segulah Medical Acceleration, Hadean Ventures, Faro Capital, Torna Kapital AB, LU Holding AB, and Gunnar Nilsson's Cancer Foundation for EUR 500 million.

SAGA Diagnostics provides ultrasensitive services and products to improve precision cancer medicine, provide more accurate treatment monitoring, and improve patient survival using minimally invasive liquid biopsy cancer testing services and kits. The company’s proprietary tests help oncologists, patients, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity. In addition, the company’s product line includes SAGAsafe, which is based on digital PCR and detects and quantifies mutations with unique ultra-sensitivity to 0. 001% mutant allele frequency (MAF); SAGASIGN, a hybrid method that monitors responses to therapy, MRD (minimal residual disease), and recurrences; and SAGASEQ, a third platform technology for enhanced sequencing library preparation together with AI/machine learning bioinformatics to reduce sequencing noise and increase true-positive signal.

As of January 2023, the firm is engaged in research-oriented studies in breast cancer, prostate cancer, melanoma, colorectal cancer, lung cancer, ovarian cancer, and AML.